# BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Appoints Evofem CEO Saundra Pelletier to Board of Directors

Aditxt (NASDAQ: ADTX) has appointed Saundra Pelletier, CEO of Evofem Biosciences (OTCPK: EVFM), to its Board of Directors as the company advances toward commercialization and sharpens its focus on women’s health. Pelletier brings more than 30 years of global pharmaceutical experience, including launching and expanding brands across women’s reproductive health. At Evofem, she led the approval and commercial growth of Phexxi(R) and the acquisition of SOLOSEC(R), marking four straight years of net sales growth. She also holds board roles at Windtree Therapeutics (NASDAQ: WINT) and serves on nonprofit advisory boards focused on women’s empowerment and health.

 To view the full press release, visit https://ibn.fm/4cXID

 About Aditxt Inc.

 Aditxt is an innovation platform dedicated to accelerating promising health innovations. Aditxt’s ecosystem of research institutions, industry partners and shareholders collaboratively drives its mission to “Make Promising Innovations Possible Together.” The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder’s voice is heard and valued, and empowers collective progress. Aditxt currently operates two programs focused on immune health and precision health. The company plans to introduce two additional programs dedicated to public health and women’s health. For these, Aditxt has entered into an arrangement agreement with Appili Therapeutics Inc. (TSX: APLI) (OTC: APLIF), which focuses on infectious diseases, and a merger agreement with Evofem. Each program will be designed to function autonomously while collectively advancing Aditxt’s mission of discovering, developing and deploying innovative health solutions to tackle some of the most urgent health challenges. The closing of the transactions with Appili and Evofem is subject to several conditions, including but not limited to approval of the transactions by the respective target shareholders and Aditxt raising sufficient capital to fund its obligations at closing. No assurance can be given that all of the conditions to closing will be obtained or satisfied or that either of the transactions will ultimately close. For more information, please visit www.Aditxt.com.

 NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

 About BioMedWire

 BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

 BMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.BioMedWire.com

 Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

 BioMedWireAustin, Texaswww.BioMedWire.com512.354.7000 OfficeEditor@BioMedWire.com

 BioMedWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/bmw/biomednewsbreaks-aditxt-inc-nasdaq-adtx-appoints-evofem-ceo-saundra-pelletier-to-board-of-directors/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/aditxt-strengthens-board-with-women-s-health-leader-saundra-pelletier/9f50518c18def15a234544dbff0aa35e) 

 



[Reddit Post](https://www.reddit.com/r/Business_NewsRamp/comments/1l74v2m/aditxt_strengthens_board_with_womens_health/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/256/9/glowU_Jr.webp)